Molbio Diagnostics Limited
Promoters Sriram Natarajan · Chandrasekhar Bhaskaran Nair · Sangeetha Sriram · Shiva Sriram · Sowmya Sriram · Exxora Trading LLP
Against an issue price of ₹807. Split- and bonus-adjusted official closes — a past move, never a forecast.
Molbio Diagnostics Limited raised ₹1,760 crore through a mainboard initial public offer.
The filing places it in Healthcare Services and names six promoters: Sriram Natarajan, Chandrasekhar Bhaskaran Nair, Sangeetha Sriram, Shiva Sriram, Sowmya Sriram and Exxora Trading LLP.
The book was open from 10 August 2026 to 12 August 2026.
The issue was priced at ₹807 a share, from a band of ₹768 to ₹807.
As of the exchange's 12-Aug-2026 19:00:00 update the book was subscribed 70.3 times the shares on offer, counting bids on NSE and BSE together.
Against their reserved portions: qualified institutional buyers 186.39 times, non-institutional investors 49.80 times, retail investors 12.96 times and employees 13.28 times. Those portions add up to the whole offer; the sub-categories below each one are already counted inside it.
4.46 crore shares were bid at cut-off — applications that accept whatever price the issue is finally set at rather than naming one.
33 anchor investors were allotted shares before the book opened, worth ₹281 crore.
The shares listed on 17 August 2026.
The last official close on file is ₹1,219 (21 September 2026), which is 51.0% above the issue price.
It now trades as MOLBIO, and its filed financials are on its company page.
Shares sold in the issue at ₹807 last closed at ₹1,218.8.
See MOLBIO’s filed financials and price history →Official exchange closes, restated for splits, bonuses and rights issues since listing. A record of past price movement, not a forecast.
- Registrar
- KFin Technologies Limited
- Lead managers
- Kotak Mahindra Capital Company Limited
- IIFL Capital Services Limited
- Jefferies India Private Limited
- Motilal Oswal Investment Advisors Limited
- Bidding opens10 Aug 2026
- Bidding closes12 Aug 2026
- Basis of allotmentnot published
Not published in the exchange feeds we ingest — we do not estimate it.
- Listing17 Aug 2026
Investors have bid for 70.26 times the shares on offer. Each category below has its own reserved portion, and those portions add up to the whole offer.
Bids placed on NSE alone, excluding BSE. It is smaller than the 70.26x headline above and the two must never be compared or added together.
Every bid names a price, or accepts whatever the final price turns out to be. This shows how many shares have been bid for at each price or above it — so the bar at the top of the band counts only the bids willing to pay it.
The columns are near-identical because they are: demand falls only 0.03% between ₹768 and ₹807, so almost every bid was willing to pay the top of the band. The axis starts at zero — the flatness is the finding, not a missing scale.
These accept whatever price the issue is finally set at, so they have no place on the price axis and are not in the chart.
How much of the demand falls away between the bottom and the top of the band.
Cumulative shares bid at or above each price in the band, from the exchange's own demand schedule. Bids placed at cut-off carry no price and are counted separately.
Anchor investors are institutions allotted shares one working day before public bidding opens, at a price fixed then. Their shares are locked in for a set period. At least 9 of them are domestic mutual funds; we could not classify 23 of the names either way.
| GOLDMAN SACHS FUNDS - GOLDMAN SACHS INDIA EQUITY PORTFOLIO | ₹25 cr |
| BLACKROCK GLOBAL FUNDS - INDIA FUND | ₹20 cr |
| INTERNATIONAL FINANCE CORPORATION* | ₹20 cr |
| MIRAE ASSET HEALTHCARE FUND MIRAHCFD | ₹20 cr |
| NIPPON LIFE INDIA TRUSTEE LTD-A/C NIPPON INDIA PHARMA FUND RCT-RPFmutual fund | ₹20 cr |
| ICICI PRUDENTIAL QUALITY FUND | ₹15 cr |
| ICICI PRUDENTIAL EXPORTS AND SERVICES FUND | ₹12 cr |
| KOTAK CONTRA FUND | ₹11.7 cr |
| KOTAK MAHINDRA TRUSTEE CO LTD A/C KOTAK HEALTHCARE FUNDmutual fund | ₹11.7 cr |
| KOTAK MAHINDRA TRUSTEE CO LTD A/C KOTAK CONSUMPTION FUNDmutual fund | ₹11.7 cr |
| HDFC MUTUAL FUND - HDFC PHARMA AND HEALTHCARE FUNDmutual fund | ₹11.1 cr |
| MOTILAL OSWAL LARGE CAP FUND | ₹10 cr |
| TATA INDIA PHARMA & HEALTHCARE FUND | ₹10 cr |
| NIPPON LIFE INDIA TRUSTEE LTD-A/C NIPPON INDIA INNOVATION FUNDmutual fund | ₹10 cr |
| HDFC VALUE FUND | ₹8.8 cr |
| HDFC MUTUAL FUND - HDFC INNOVATION FUNDmutual fund | ₹8.7 cr |
| EDELWEISS TRUSTEESHIP CO LTD AC - EDELWEISS MF AC - EDELWEISS EQUITY SAVINGS FUNDmutual fund | ₹7.5 cr |
| HDFC LIFE INSURANCE COMPANY LIMITED | ₹7.1 cr |
| BAJAJ LIFE INSURANCE LIMITED | ₹7.1 cr |
| WHITEOAK CAPITAL PHARMA AND HEALTHCARE FUND | ₹6.5 cr |
| HDFC MUTUAL FUND - HDFC MNC FUNDmutual fund | ₹6.4 cr |
| GOLDMAN SACHS ETF TRUST - GOLDMAN SACHS INDIA EQUITY ETF | ₹5 cr |
| WHITEOAK CAPITAL AGGRESSIVE HYBRID FUND | ₹3.5 cr |
| ISIF EQUITY LONG-SHORT FUND | ₹3 cr |
| AXIS MAX LIFE INSURANCE LIMITED A/C SUSTAINABLE EQUITY FUND - ULIF02505/10/21SUSTAINEQU104 | ₹2.8 cr |
| AXIS MAX LIFE INSURANCE LIMITED A/C - ULIF00225/06/04LIFEBALANC104 - BALANCED FUND | ₹2.7 cr |
| EDELWEISS TRUSTEESHIP CO LTD AC - EDELWEISS MF AC- EDELWEISS RECENTLY LISTED IPO FUNDmutual fund | ₹2.5 cr |
| AXIS MAX LIFE INSURANCE LIMITED PENSION MAXIMISER FUND (ULIF01715/02/13PENSMAXIMI104) | ₹0.9 cr |
| AXIS MAX LIFE INSURANCE LIMITED A/C UHG2S - INDIA CONSUMPTION OPPORTUNITIES FUND | ₹0.2 cr |
| AXIS MAX LIFE INSURANCE LIMITED A/C UMFPH - HIGH GROWTH PENSION FUND | ₹0.2 cr |
| AXIS MAX LIFE INSURANCE LIMITED A/C - ULGF00217/04/06GRATBALANC104 - GROUP GRATUITY BALANCED FUND | ₹0.1 cr |
| AXIS MAX LIFE INSURANCE LIMITED A/C - ULIF00625/11/05PENSBALANC104 - PENSION BALANCED FUND | ₹0.1 cr |
| AXIS MAX LIFE INSURANCE LIMITED PENSION PRESERVER FUND(ULIF01815/02/13PENSPRESER104) | ₹0.1 cr |
From the issuer’s anchor allotment filing. A record of who was allotted what — not a recommendation.
- Anchor investors — first trancheSEBI ICDR 2018 Reg. 32(5)(b) — 50% of the anchor allocation, 30 days from allotment16 Sept 202650% of this tranche
- Anchor investors — second trancheSEBI ICDR 2018 Reg. 32(5)(a) — the remaining 50% of the anchor allocation, 90 days from allotment15 Nov 202650% of this tranche
- All other pre-issue capitalSEBI ICDR 2018 Reg. 17 — all other pre-issue capital, 6 months from allotment17 Feb 2027whole tranche releases on this date
- Promoters' minimum contributionSEBI ICDR 2018 Reg. 16(1)(a) — promoters' minimum contribution, 18 months from allotment17 Feb 2028whole tranche releases on this date
Computed from the SEBI ICDR 2018 lock-in rules, not disclosed by the issuer or the exchange. The regulation counts from the date of allotment, which no feed we ingest publishes, so these are counted from the listing date and fall at most two to three business days later than the true expiry.
Every offer document must set out the reasoning behind its own price: what the company earned in the years before it came to market, and what multiple of those earnings it is asking for. This is that chapter — the issuer’s argument for its price, not our assessment of it.
| Year | Basic | Diluted | Weight |
|---|---|---|---|
| FY2024 | ₹9.05 | ₹9.04 | 1 |
| FY2025 | ₹12.87 | ₹12.87 | 2 |
| FY2026 | ₹14.77 | ₹14.77 | 3 |
Figures as printed in the offer document's "Basis for Offer Price" chapter. A record of the case the issuer made for its own price, not our valuation of it.
Everything we extracted from this issue's offer document is the pricing justification rather than the restated statements — it is shown under how the offer was priced. The restated financial statements themselves have not been extracted for this issue.
We have not extracted this section from the offer document for this issue yet. It is read from the abridged prospectus, and several offer documents are served as .zip archives or as scanned pages with no text layer.
The offer document must name the listed companies the issuer considers comparable, and print their valuation figures beside its own. This is that list — the issuer’s choice of comparison, not ours.
| Company | P/E | P/B | RoNW | EPS | Income |
|---|---|---|---|---|---|
| Dr. Lal Path Labs Ltd. | 27,629.1 | — | 20.8% | 30.24 | ₹27,629 cr |
| Metropolis Healthcare Limited | 16,458.5 | — | 12.6% | 9.19 | ₹16,458 cr |
| Poly Medicure Limited | 18,752.6 | — | 10.4% | 31.79 | ₹18,753 cr |
| Vijaya Diagnostics Centre Limitednot in our universe | 8,142.0 | — | 18.1% | 16.81 | ₹8,142 cr |
The issuer's own figures as printed at the head of the same table — its claim about itself, on the same basis as its claims about the companies below.
Figures as PRINTED by the issuer in its own offer document. The comparison set is the issuer's choice, not ours.
| Firm | Issues | Typical listing move | Below issue @30d | @90d | @180d |
|---|---|---|---|---|---|
IIFL Capital Services Limited 2024 – 2026 | 29 12 measurable | +17.3% | 1 of 5 | — | 0 of 2 |
Jefferies India Private Limited 2022 – 2026 | 25 4 measurable | +21.1% | 2 of 5 | — | — |
Kotak Mahindra Capital Company 2021 – 2026 | 64 15 measurable | +16.6% | 3 of 14 | 1 of 3 | 2 of 4 |
Motilal Oswal Investment Advisors Limited 2022 – 2026 | 40 8 measurable | +22.8% | 2 of 5 | 0 of 1 | — |
| Firm | Issues | Typical listing move | Below issue @30d | @90d | @180d |
|---|---|---|---|---|---|
Kfin Technologies Limited 2021 – 2026 | 126 30 measurable | +7.9% | 8 of 18 | 2 of 5 | 2 of 5 |
A count of what happened to the other issues each firm was named on, computed from exchange closes. Not a rating, not a ranking, and not a view on the firm.
- Prospectus· PDF · exchange archive14 Aug 2026
- Red herring prospectus (RHP)· ZIP · exchange archive3 Aug 2026
- Red herring prospectus (RHP)· ZIP · exchange archive
- Draft red herring prospectus (DRHP)· PDF · exchange archive23 Aug 2025
- Anchor investor allotment· ZIP · exchange archive
- Financial ratios advertisement· ZIP · exchange archive
- In-principle approval (XBRL)· XML · exchange archive
Filed with SEBI and the exchanges by the issuer. These are the source for every figure on this page.
Compiled from NSE and SEBI offer documents and exchange feeds. A description of the issue and of the bids received — not investment advice, and not a view on whether to apply. No grey-market premium, no allotment lookup and no listing-gain estimate is published here.